Changrui Bio is a one-stop service provider for macromolecular biopharmaceuticals CDMO. The company mainly provides carrier drug development and macromolecular biopharmaceuticals CDMO one-stop service. Recently, Buchang Pharmaceutical plans to invest 64 million yuan to increase the capital of Changrui Bio. After the completion of this capital increase, Buchang Pharmaceutical holds a 64% stake in Changrui Bio.
This article is reprinted from: https://www.itjuzi.com/merger/9209
This site is for inclusion only, and the copyright belongs to the original author.